4-1BB/TNFRSF9/CD137 Antibody (4B4-1) - Low Endotoxin, Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-09103

Clone 4B4-1 was used by HLDA to establish CD designation.
Catalog #
Availability
Size / Price
Qty
NBP3-09103
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human, Primate

Applications

ELISA, Flow Cytometry, Immunoprecipitation, Functional

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 kappa Clone # 4B4-1

Format

Low Endotoxin, Azide and BSA Free

Concentration

1 mg/ml

View all 4-1BB/TNFRSF9/CD137 Antibodies »

Product Specifications

Immunogen

Recombinant human 4-1BB/TNFRSF9/CD137 ectodomain

Specificity

The mouse monoclonal antibody 4B4-1 recognizes an extracellular conformational epitope on CD137, an approximately 40 kDa type I transmembrane protein of the TNFR family expressed mainly on activated T cells.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1 kappa

Endotoxin Level

Endotoxin level is less than 0.01 EU/ug of the protein, as determined by the LAL test.

Scientific Data Images

Flow Cytometry: 4-1BB/TNFRSF9/CD137 Antibody (4B4-1) - Low Endotoxin, Azide and BSA Free [NBP3-09103]

Flow Cytometry: 4-1BB/TNFRSF9/CD137 Antibody (4B4-1) - Low Endotoxin, Azide and BSA Free [NBP3-09103]

Flow Cytometry: 4-1BB/TNFRSF9/CD137 Antibody (4B4-1) - Low Endotoxin, Azide and BSA Free [NBP3-09103] - Separation of cells stained using anti-humam CD137 (4B4-1) purified antibody (low endotoxin, concentration in sample 4 ug/ml, GAM APC, red-filled) from cells unstained by primary antibody (GAM APC, black-dashed) in flow cytometry analysis (surface staining) of human PHA stimulated peripheral blood mononuclear cell suspension.
Flow Cytometry: 4-1BB/TNFRSF9/CD137 Antibody (4B4-1) - Low Endotoxin, Azide and BSA Free [NBP3-09103]

Flow Cytometry: 4-1BB/TNFRSF9/CD137 Antibody (4B4-1) - Low Endotoxin, Azide and BSA Free [NBP3-09103]

Flow Cytometry: 4-1BB/TNFRSF9/CD137 Antibody (4B4-1) - Low Endotoxin, Azide and BSA Free [NBP3-09103] - Surface staining pattern of human PHA stimulated peripheral blood mononuclear cell suspension stained using anti-humam CD137 (4B4-1) purified antibody (low endotoxin, concentration in sample 4 ug/ml) GAM APC.

Applications

Application
Recommended Usage

Flow Cytometry

1-4 ug/ml

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

Phosphate buffered saline (PBS), pH 7.4

Format

Low Endotoxin, Azide and BSA Free

Preservative

No Preservative

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C. Do not freeze.

Background: 4-1BB/TNFRSF9/CD137

4-1BB, also called CD137 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9), is a type I surface glycoprotein expressed on activated T cell and natural killer (NK) cells (1,2). Human 4-1BB protein is 255 amino acids (aa) in length with a theoretical molecular weight of 28 kDa. It contains an extracellular domain, a helical transmembrane domain, and a cytoplasmic/intracellular domain (3). 4-1BB/TNFRSF9/CD137 is a costimulatory receptor that binds the ligand 4-1BBL/CD137L which is primarily expressed on antigen presenting cells (APCs) such as dendritic cells (DCs), macrophages, and B cells (1,2,4,5). The 4-1BB receptor-ligand interaction results in recruitment of TNFR-associated factor (TRAF) family adaptor proteins to 4-1BB's cytoplasmic domain (1,2,4,5). TRAF1, TRAF2, and TRAF3 are found in various homodimer and/or heterodimer configurations. Their recruitment to 4-1BB/CD137 initiates signalosome formation as well as activation of the nuclear factor-kappa B (NF-kappaB) and mitogen-activated protein kinase (MAPK) signaling cascade (1,4,5). 4-1BB/TNFRSF9/CD137 stimulation leads to increased cellular cytotoxic activity and pro-inflammatory cytokine production (1,2,4). Given its role in immune cell activation, 4-1BB has become a promising target for cancer immunotherapy (1,2,4). Current approaches to target 4-1BB include agonistic monoclonal and bispecific anti-4-1BB antibodies and well as utilizing the cytoplasmic domain of 4-1BB in generating chimeric antigen receptors (CARs) (1,2,4). 4-1BB agonists in clinical trials include Urelumab and Utolimumab. Utolimumab also has ligand blocking properties whereas Urelumab does not (1,2,4). Anti-4-1BB monoclonal antibodies are being tested as monotherapy as well as combination therapy with either other immunostimulatory monoclonal antibodies or with checkpoint blockade antibodies like anti-PD-1 (1,2,4).

References

1. Etxeberria, I., Glez-Vaz, J., Teijeira, A., & Melero, I. (2020). New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO open, 4(Suppl 3), e000733. https://doi.org/10.1136/esmoopen-2020-000733

2. Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018). Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood, 131(1), 49-57. https://doi.org/10.1182/blood-2017-06-741041

3. Uniport (Q07011)

4. Chester, C., Ambulkar, S., & Kohrt, H. E. (2016). 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunology, Immunotherapy: CII, 65(10), 1243-1248. https://doi.org/10.1007/s00262-016-1829-2

5. Zapata, J. M., Perez-Chacon, G., Carr-Baena, P., Martinez-Forero, I., Azpilikueta, A., Otano, I., & Melero, I. (2018). CD137 (4-1BB) signalosome: complexity is a matter of TRAFs. Frontiers in Immunology, 9, 2618. https://doi.org/10.3389/fimmu.2018.02618

Alternate Names

41BB, CD137, ILA, TNFRSF9

Gene Symbol

TNFRSF9

Additional 4-1BB/TNFRSF9/CD137 Products

Product Documents

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy Policy
Cookie Policy
Site Map
© Copyright 2026 Bio-Techne. All Rights Reserved. All trademarks and registered trademarks are the property of Bio-Techne and its brands unless otherwise specified.